Literature DB >> 17317146

MeCP2 in Rett syndrome: transcriptional repressor or chromatin architectural protein?

Lisa Helbling Chadwick1, Paul A Wade.   

Abstract

Rett syndrome is a progressive neurological disorder caused by mutations in the methyl-DNA binding protein MeCP2. The longstanding model depicting MeCP2 as a transcriptional repressor predicts that the Rett syndrome phenotype probably results from misregulation of MeCP2 target genes. Somewhat unexpectedly, the identification of such targets has proven challenging. The recent identification of two MeCP2 targets, BDNF and DLX5, are suggestive of two very different roles for this protein--one as a classical repressor protein, and the other as a mediator of a complex, specialized chromatin structure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17317146     DOI: 10.1016/j.gde.2007.02.003

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  21 in total

Review 1.  Epigenetic principles and mechanisms underlying nervous system functions in health and disease.

Authors:  Mark F Mehler
Journal:  Prog Neurobiol       Date:  2008-10-17       Impact factor: 11.685

2.  MeCP2 binds cooperatively to its substrate and competes with histone H1 for chromatin binding sites.

Authors:  Rajarshi P Ghosh; Rachel A Horowitz-Scherer; Tatiana Nikitina; Luda S Shlyakhtenko; Christopher L Woodcock
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

Review 3.  Rett syndrome and MeCP2.

Authors:  Vichithra R B Liyanage; Mojgan Rastegar
Journal:  Neuromolecular Med       Date:  2014-03-11       Impact factor: 3.843

Review 4.  Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression.

Authors:  Renaud Massart; Raymond Mongeau; Laurence Lanfumey
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-09-05       Impact factor: 6.237

5.  Unique physical properties and interactions of the domains of methylated DNA binding protein 2.

Authors:  Rajarshi P Ghosh; Tatiana Nikitina; Rachel A Horowitz-Scherer; Lila M Gierasch; Vladimir N Uversky; Kristopher Hite; Jeffrey C Hansen; Christopher L Woodcock
Journal:  Biochemistry       Date:  2010-05-25       Impact factor: 3.162

6.  Bone mass in Rett syndrome: association with clinical parameters and MECP2 mutations.

Authors:  Jay R Shapiro; Genila Bibat; Girish Hiremath; Mary E Blue; Shilpa Hundalani; Theodore Yablonski; Aditi Kantipuly; Charles Rohde; Michael Johnston; Sakkubai Naidu
Journal:  Pediatr Res       Date:  2010-11       Impact factor: 3.756

7.  DLX5 and DLX6 expression is biallelic and not modulated by MeCP2 deficiency.

Authors:  Birgitt Schüle; Hong Hua Li; Claudia Fisch-Kohl; Carolin Purmann; Uta Francke
Journal:  Am J Hum Genet       Date:  2007-08-02       Impact factor: 11.025

8.  Analysis of protein domains and Rett syndrome mutations indicate that multiple regions influence chromatin-binding dynamics of the chromatin-associated protein MECP2 in vivo.

Authors:  Asmita Kumar; Sachin Kamboj; Barbara M Malone; Shinichi Kudo; Jeffery L Twiss; Kirk J Czymmek; Janine M LaSalle; N Carolyn Schanen
Journal:  J Cell Sci       Date:  2008-03-11       Impact factor: 5.285

9.  Mecp2 deficiency decreases bone formation and reduces bone volume in a rodent model of Rett syndrome.

Authors:  R D O'Connor; M Zayzafoon; M C Farach-Carson; N C Schanen
Journal:  Bone       Date:  2009-05-03       Impact factor: 4.398

Review 10.  DNA methylation and methyl-CpG binding proteins: developmental requirements and function.

Authors:  Ozren Bogdanović; Gert Jan C Veenstra
Journal:  Chromosoma       Date:  2009-06-09       Impact factor: 4.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.